Developing Targeted Therapeutics for Human Health
ShigaTek™ is a vectoring molecule targeting a novel cell-surface receptor specific to the STxB™ subunit. STxB™ Pharma Technologies Inc. anticipates numerous products to emerge from the ShigaTek™ platform in both core areas of focus:
- Therapeutic vaccines for cancers and infectious diseases;
- Targeting to the STxB receptor for cancer and a variety of orphan diseases.
The Company will be seeking industrial partnerships in both therapeutic areas in order to continue to build and develop a strong product pipeline.
"STxB™ Pharma Technologies Inc. (SPT) is a Canadian-based company, established to develop and commercialize the STxB™ (ShigaTek™) technology platform. ShigaTek™ was initially derived in laboratories at the Institut Curie and the Hopital Georges Pompidou in Paris, France. Certain aspects were also derived at the Hospital for Sick Children in Toronto, Canada.
Who We Are
STxB™ Pharma Technologies Inc. is clinical-stage development company with registered Head Office and research activities in the Charlottetown, PEI BioCluster and an office the Greater Toronto Area (GTA) in Canada. The principals have also established ImmunoTargets SAS, a Young Innovative Company, in Paris, France to conduct development work on certain ShigaTek™ - based products in Paris and Europe.